# ECLYPse (NCT06640166)

> Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06640166
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Conditions: Colorectal Carcinoma; Colorectal Neoplasms; Colorectal Tumor; Colorectal Adenocarcinoma; Colorectal Cancer (CRC); Colorectal Cancer; Colon Cancer; Colon Adenocarcinoma; Colon Carcinoma; Colon Neoplasm
- Interventions: encorafenib + cetuximab + FOLFIRI
- Enrollment: 25
- Primary outcome: 6-month Progression Free Survival rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 12
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=eclypse-nct06640166

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06640166", "email": "<work email>"}; the inbox owner confirms by the emailed link.